HC Wainwright reissued their buy rating on shares of Alimera Sciences, Inc. (NASDAQ:ALIM) in a research report sent to investors on Friday. The brokerage currently has a $5.00 price target on the biopharmaceutical company’s stock.

ALIM has been the subject of several other research reports. Cowen and Company set a $3.00 price target on shares of Alimera Sciences and gave the company a buy rating in a research report on Tuesday, July 25th. Zacks Investment Research raised shares of Alimera Sciences from a sell rating to a hold rating in a research report on Tuesday, August 29th. Finally, ValuEngine downgraded shares of Alimera Sciences from a sell rating to a strong sell rating in a research report on Monday, September 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and an average target price of $3.38.

Alimera Sciences (NASDAQ ALIM) traded up 0.81% during trading on Friday, hitting $1.25. The stock had a trading volume of 112,499 shares. The stock’s 50-day moving average price is $1.35 and its 200-day moving average price is $1.42. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $1.72. The company’s market capitalization is $86.31 million.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million for the quarter, compared to the consensus estimate of $10.20 million. Alimera Sciences’s revenue was up 8.3% on a year-over-year basis. During the same period last year, the business earned ($0.17) EPS. Analysts expect that Alimera Sciences will post ($0.21) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/28/alimera-sciences-inc-alim-receives-buy-rating-from-hc-wainwright.html.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. JW Asset Management LLC increased its position in shares of Alimera Sciences by 15.6% during the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after acquiring an additional 130,000 shares in the last quarter. Kennedy Capital Management Inc. bought a new stake in Alimera Sciences in the 1st quarter worth approximately $467,000. PNC Financial Services Group Inc. grew its position in Alimera Sciences by 24.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 35,200 shares during the period. Finally, KCG Holdings Inc. grew its position in Alimera Sciences by 127.0% in the 1st quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 43,977 shares during the period. 37.20% of the stock is owned by institutional investors.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.